NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000002110

Registered date:23/06/2009

Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedrheumatoid arthritis
Date of first enrollment2006/07/01
Target sample size100
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeAfter discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 1 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 1 year.
Secondary OutcomeAfter discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 2 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 2 year.

Key inclusion & exclusion criteria

Age minimum18years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatients who met the following criteria are excluded. 1) patients who are already in remission and do not use infliximab 2) control with less than 5mg/day of PSL 3) PSL was increased within 4 weeks before the study 4) patients who are not appropriate to the study by a doctor's judgement

Related Information

Contact

public contact
Name Kazuyoshi Saito
Address 1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555, Japan Japan
Telephone 093-603-1611
E-mail tanaka@med.uoeh-u.ac.jp
Affiliation School of Medicine, University of Occupational and Environmental Health, Japan First Department of Internal Medicine
scientific contact
Name Yoshiya Tanaka
Address 1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555, Japan Japan
Telephone 093-603-1611
E-mail tanaka@med.uoeh-u.ac.jp
Affiliation School of Medicine, University of Occupational and Environmental Health, Japan First Department of Internal Medicine